OBJECTIVES: B-cell depletion time after rituximab (RTX) treatment is prolonged in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) compared with other autoimmune diseases. We investigated central and peripheral B-cell development to identify the causes for the defect in B-cell reconstitution after RTX therapy. METHODS: We recruited 91 patients with AAV and performed deep phenotyping of the peripheral and bone marrow B-cell compartment by spectral flow and mass cytometry. B-cell development was studied by in vitro modelling and the role of BAFF receptor by quantitative PCR, western blot analysis and in vitro assays. RESULTS: Treatment-naïve patients with AAV showed low transitional B-cell numbers, suggesting impaired B-lymphopoiesis. We analysed bone marrow of treatment-naïve and RTX-treated patients with AAV and found reduced B-lymphoid precursors. In vitro modelling of B-lymphopoiesis from AAV haematopoietic stem cells showed intact, but slower and reduced immature B-cell development. In a subgroup of patients, after RTX treatment, the presence of transitional B cells did not translate in replenishment of naïve B cells, suggesting an impairment in peripheral B-cell maturation. We found low BAFF-receptor expression on B cells of RTX-treated patients with AAV, resulting in reduced survival in response to BAFF in vitro. CONCLUSIONS: Prolonged depletion of B cells in patients with AAV after RTX therapy indicates a B-cell defect that is unmasked by RTX treatment. Our data indicate that impaired bone marrow B-lymphopoiesis results in a delayed recovery of peripheral B cells that may be further aggravated by a survival defect of B cells. Our findings contribute to the understanding of AAV pathogenesis and may have clinical implications regarding RTX retreatment schedules and immunomonitoring after RTX therapy.

Centre of Chronic Immunodeficiency Medical Center University of Freiburg Faculty of Medicine University of Freiburg Freiburg Germany

CIBSS Centre for Integrative Biological Signalling Studies University of Freiburg Freiburg Germany

Department of Orthopedics and Trauma Surgery University of Freiburg Freiburg im Breisgau Germany

Department of Paediatric Haematology and Oncology University Hospital Motol Prague Czech Republic

Department of Rheumatology and Clinical Immunology Faculty of Medicine University of Freiburg Freiburg im Breisgau Germany

Division of Clinical and Experimental Immunology Institute of Immunology Center for Pathophysiology Infectiology and Immunology Medical University of Vienna Vienna Austria

Division of Rheumatology and Clinical Immunology Medical University of Graz Graz Austria

Medical Physics Department Consejo Nacional de Investigaciones Científicas y Técnicas Bariloche Argentina

Zobrazit více v PubMed

Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221–32. doi: 10.1056/NEJMoa0909905. PubMed DOI PMC

Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371:1771–80. doi: 10.1056/NEJMoa1404231. PubMed DOI

Terrier B, Pagnoux C, Perrodeau É, et al. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. Ann Rheum Dis. 2018;77:1150–6. doi: 10.1136/annrheumdis-2017-212768. PubMed DOI

Fussner LA, Hummel AM, Schroeder DR, et al. Factors determining the clinical utility of serial measurements of antineutrophil cytoplasmic antibodies targeting proteinase 3. Arthritis Rheumatol. 2016;68:1700–10. doi: 10.1002/art.39637. PubMed DOI PMC

Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med. 2013;369:417–27. doi: 10.1056/NEJMoa1213277. PubMed DOI PMC

Roll P, Palanichamy A, Kneitz C, et al. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum. 2006;54:2377–86. doi: 10.1002/art.22019. PubMed DOI

Hellmich B, Sanchez-Alamo B, Schirmer JH, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2024;83:30–47. doi: 10.1136/ard-2022-223764. PubMed DOI

Thiel J, Salzer U, Hässler F, et al. B cell homeostasis is disturbed by immunosuppressive therapies in patients with ANCA-associated vasculitides. Autoimmunity. 2013;46:429–38. doi: 10.3109/08916934.2013.798652. PubMed DOI

Thiel J, Rizzi M, Engesser M, et al. B cell Repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients. Arthritis Res Ther. 2017;19:101. doi: 10.1186/s13075-017-1306-0. PubMed DOI PMC

Venhoff N, Niessen L, Kreuzaler M, et al. Reconstitution of the peripheral B lymphocyte compartment in patients with ANCA-associated vasculitides treated with rituximab for relapsing or refractory disease. Autoimmunity. 2014;47:401–8. doi: 10.3109/08916934.2014.914174. PubMed DOI

Venhoff N, Effelsberg NM, Salzer U, et al. Impact of Rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides. PLoS ONE. 2012;7:e37626. doi: 10.1371/journal.pone.0037626. PubMed DOI PMC

Mescia F, Salviani C, Tonoli M, et al. Sustained post-rituximab B-cell depletion is common in ANCA-associated vasculitis and is affected by sex and renal function. Nephrol Dial Transplant. 2024;39:683–93. doi: 10.1093/ndt/gfad197. PubMed DOI

Gathmann B, Mahlaoui N, Gérard L, et al. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol. 2014;134:116–26. doi: 10.1016/j.jaci.2013.12.1077. PubMed DOI

Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis. 2009;68:25–32. doi: 10.1136/ard.2007.083188. PubMed DOI PMC

Tieu J, Smith RM, Gopaluni S, et al. Rituximab associated hypogammaglobulinemia in autoimmune disease. Front Immunol. 2021;12:671503. doi: 10.3389/fimmu.2021.671503. PubMed DOI PMC

van Vollenhoven RF, Emery P, Bingham CO, III, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72:1496–502. doi: 10.1136/annrheumdis-2012-201956. PubMed DOI PMC

Korzhenevich J, Janowska I, van der Burg M, et al. Human and mouse early B cell development: so similar but so different. Immunol Lett. 2023;261:1–12. doi: 10.1016/j.imlet.2023.07.004. PubMed DOI

Warnatz K, Salzer U, Rizzi M, et al. B-cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humans. Proc Natl Acad Sci USA. 2009;106:13945–50. doi: 10.1073/pnas.0903543106. PubMed DOI PMC

Carsetti R, Rosado MM, Wardmann H. Peripheral development of B cells in mouse and man. Immunol Rev. 2004;197:179–91. doi: 10.1111/j.0105-2896.2004.0109.x. PubMed DOI

Jenks SA, Cashman KS, Woodruff MC, et al. Extrafollicular responses in humans and SLE. Immunol Rev. 2019;288:136–48. doi: 10.1111/imr.12741. PubMed DOI PMC

Anolik JH, Friedberg JW, Zheng B, et al. B cell reconstitution after Rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol. 2007;122:139–45. doi: 10.1016/j.clim.2006.08.009. PubMed DOI

Stuchly J, Novak D, Brdickova N, et al. Deconstructing complexity: a computational topology approach to trajectory inference in the human thymus with Tviblindi. Immunology. 2023 doi: 10.1101/2023.07.13.547329. Preprint. DOI

Bakardjieva M, Stuchlý J, Pelák O, et al. Tviblindi algorithm identifies branching developmental Trajectories of human B cell development. Immunology. 2023 doi: 10.1101/2024.01.11.575178. Preprint. PubMed DOI PMC

Kraus H, Kaiser S, Aumann K, et al. A feeder-free differentiation system identifies autonomously proliferating B cell precursors in human bone marrow. J Immunol. 2014;192:1044–54. doi: 10.4049/jimmunol.1301815. PubMed DOI

Troilo A, Wehr C, Janowska I, et al. Nonpermissive bone marrow environment impairs early B-cell development in common variable immunodeficiency. Blood. 2020;135:1452–7. doi: 10.1182/blood.2019003855. PubMed DOI PMC

Smulski CR, Eibel H. BAFF and BAFF-receptor in B cell selection and survival. Front Immunol. 2018;9:2285. doi: 10.3389/fimmu.2018.02285. PubMed DOI PMC

Kreuzaler M, Rauch M, Salzer U, et al. Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors. J Immunol. 2012;188:497–503. doi: 10.4049/jimmunol.1102321. PubMed DOI

Smulski CR, Kury P, Seidel LM, et al. BAFF- and TACI-dependent processing of BAFFR by ADAM proteases regulates the survival of B cells. Cell Rep. 2017;18:2189–202. doi: 10.1016/j.celrep.2017.02.005. PubMed DOI

Elmér E, Smargianaki S, Pettersson Å, et al. Increased frequencies of switched memory B cells and plasmablasts in peripheral blood from patients with ANCA-associated vasculitis. J Immunol Res. 2020;2020:8209737. doi: 10.1155/2020/8209737. PubMed DOI PMC

McLean KC, Mandal M. It takes three receptors to raise a B cell. Trends Immunol. 2020;41:629–42. doi: 10.1016/j.it.2020.05.003. PubMed DOI PMC

Zehentmeier S, Pereira JP. Cell circuits and niches controlling B cell development. Immunol Rev. 2019;289:142–57. doi: 10.1111/imr.12749. PubMed DOI PMC

Venhoff N, Thiel J, Voll R, et al. THU0341 FLT3 ligand concentrations are elevated in ANCA-associated vasculitides (AAV) and are influenced by immunosuppressive therapy. Annals of the Rheumatic Diseases. 2017;76:332

Hirayama F, Clark SC, Ogawa M. Negative regulation of early B Lymphopoiesis by interleukin 3 And interleukin 1 alpha. Proc Natl Acad Sci U S A. 1994;91:469–73. doi: 10.1073/pnas.91.2.469. PubMed DOI PMC

Kennedy DE, Knight KL. Inhibition of B lymphopoiesis by adipocytes and IL-1-producing myeloid-derived suppressor cells. J Immunol. 2015;195:2666–74. doi: 10.4049/jimmunol.1500957. PubMed DOI PMC

Laakko T, Fraker P. Rapid changes in the lymphopoietic and granulopoietic compartments of the marrow caused by stress levels of corticosterone. Immunology. 2002;105:111–9. doi: 10.1046/j.1365-2567.2002.01346.x. PubMed DOI PMC

Chang S-E, Guo L, Tian J, et al. Autoimmune bone marrow environment severely inhibits B cell development by inducing extensive cell death and inhibiting proliferation. Autoimmunity. 2012;45:210–7. doi: 10.3109/08916934.2011.632455. PubMed DOI

Kincade PW, Medina KL, Smithson G. Sex hormones as negative regulators of lymphopoiesis. Immunol Rev. 1994;137:119–34. doi: 10.1111/j.1600-065x.1994.tb00661.x. PubMed DOI

Rocha B, Penit C, Baron C, et al. Accumulation of bromodeoxyuridine-labeled cells in central and peripheral lymphoid organs: minimal estimates of production and turnover rates of mature lymphocytes. Eur J Immunol. 1990;20:1697–708. doi: 10.1002/eji.1830200812. PubMed DOI

Rolink AG, Andersson J, Melchers F. Characterization of immature B cells by a novel monoclonal antibody, by turnover and by mitogen reactivity. Eur J Immunol. 1998;28:3738–48. doi: 10.1002/(SICI)1521-4141(199811)28:11<3738::AID-IMMU3738>3.0.CO;2-Q. PubMed DOI

Weill JC, Weller S, Reynaud CA. Human marginal zone B cells. Annu Rev Immunol. 2009;27:267–85. doi: 10.1146/annurev.immunol.021908.132607. PubMed DOI

Gercik O, Karasu S, Solmaz D, et al. Splenic infarction is not rare in granulomatosis with polyangiitis. Clin Rheumatol. 2020;39:1929–34. doi: 10.1007/s10067-020-04993-w. PubMed DOI

Ghinoi A, Pipitone N, Cavazza A, et al. Wegener granulomatosis with spleen infarction: case report and review of the literature. Semin Arthritis Rheum. 2008;37:328–33. doi: 10.1016/j.semarthrit.2007.07.009. PubMed DOI

Becerra E, De La Torre I, Leandro MJ, et al. B cell phenotypes in patients with rheumatoid arthritis relapsing after rituximab: expression of B cell-activating factor-binding receptors on B cell Subsets. Clin Exp Immunol. 2017;190:372–83. doi: 10.1111/cei.13024. PubMed DOI PMC

Becerra E, Scully MA, Leandro MJ, et al. Effect of rituximab on B cell phenotype and serum B cell-activating factor levels in patients with thrombotic thrombocytopenic purpura. Clin Exp Immunol. 2015;179:414–25. doi: 10.1111/cei.12472. PubMed DOI PMC

de la Torre I, Moura RA, Leandro MJ, et al. B-cell-activating factor receptor expression on naive and memory B cells: relationship with relapse in patients with rheumatoid arthritis following B-cell depletion therapy. Ann Rheum Dis. 2010;69:2181–8. doi: 10.1136/ard.2010.131326. PubMed DOI

Gutierrez-Rodrigues F, Wells KV, Jones AI, et al. Clonal haematopoiesis across the age spectrum of vasculitis patients with Takayasu’s arteritis, ANCA-associated vasculitis and giant cell arteritis. Ann Rheum Dis. 2024;83:508–17. doi: 10.1136/ard-2023-224933. PubMed DOI PMC

Lord JD, Shows DM. Thiopurine use associated with reduced B and natural killer cells in inflammatory bowel disease. WJG. 2017;23:3240. doi: 10.3748/wjg.v23.i18.3240. PubMed DOI PMC

von Borstel A, Abdulahad WH, Dekkema G, et al. Mycophenolic acid and 6-mercaptopurine both inhibit B-cell proliferation in granulomatosis with polyangiitis patients, whereas only Mycophenolic acid inhibits B-cell IL-6 production. PLoS ONE. 2020;15:e0235743. doi: 10.1371/journal.pone.0235743. PubMed DOI PMC

Megías J, Yáñez A, Moriano S, et al. Direct toll-like receptor-mediated stimulation of hematopoietic stem and progenitor cells occurs in vivo and promotes differentiation toward macrophages. Stem Cells. 2012;30:1486–95. doi: 10.1002/stem.1110. PubMed DOI

Nagai Y, Garrett KP, Ohta S, et al. Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. Immunity. 2006;24:801–12. doi: 10.1016/j.immuni.2006.04.008. PubMed DOI PMC

Aluri J, Cooper MA, Schuettpelz LG. Toll-like receptor signaling in the establishment and function of the immune system. Cells. 2021;10:1374. doi: 10.3390/cells10061374. PubMed DOI PMC

Esplin BL, Shimazu T, Welner RS, et al. Chronic exposure to a TLR ligand Injures hematopoietic stem cells. J Immunol. 2011;186:5367–75. doi: 10.4049/jimmunol.1003438. PubMed DOI PMC

Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum. 1990;33:1101–7. doi: 10.1002/art.1780330807. PubMed DOI

Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and Angiitis) Arthritis Rheum. 1990;33:1094–100. doi: 10.1002/art.1780330806. PubMed DOI

Grayson PC, Ponte C, Suppiah R, et al. American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis. 2022;81:309–14. doi: 10.1136/annrheumdis-2021-221794. PubMed DOI

Robson JC, Grayson PC, Ponte C, et al. American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Ann Rheum Dis. 2022;81:315–20. doi: 10.1136/annrheumdis-2021-221795. PubMed DOI

Suppiah R, Robson JC, Grayson PC, et al. American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. Ann Rheum Dis. 2022;81:321–6. doi: 10.1136/annrheumdis-2021-221796. PubMed DOI

Kuzilková D, Bugarin C, Rejlova K, et al. Either IL-7 activation of JAK-STAT or BEZ inhibition of Pi3K-AKT-mTOR pathways dominates the single-cell phosphosignature of ex vivo treated pediatric T-cell acute lymphoblastic leukemia cells. Haematologica. 2022;107:1293–310. doi: 10.3324/haematol.2021.278796. PubMed DOI PMC